244 related articles for article (PubMed ID: 33009446)
1. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
[TBL] [Abstract][Full Text] [Related]
2. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
4. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
5. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
6. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
7. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
[TBL] [Abstract][Full Text] [Related]
8. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
Tan CM; Nickols HH; Limbird LE
J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
[TBL] [Abstract][Full Text] [Related]
9. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
[TBL] [Abstract][Full Text] [Related]
11. V2R mutations and nephrogenic diabetes insipidus.
Bichet DG
Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
[TBL] [Abstract][Full Text] [Related]
12. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
14. AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions.
Gao C; Higgins PJ; Zhang W
Cells; 2020 Sep; 9(10):. PubMed ID: 32993088
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
16. Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.
Erdélyi LS; Mann WA; Morris-Rosendahl DJ; Groß U; Nagel M; Várnai P; Balla A; Hunyady L
Kidney Int; 2015 Nov; 88(5):1070-8. PubMed ID: 26131744
[TBL] [Abstract][Full Text] [Related]
17. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.
Wang L; Guo W; Fang C; Feng W; Huang Y; Zhang X; Liu M; Cui J
Sci Rep; 2021 May; 11(1):11057. PubMed ID: 34040143
[TBL] [Abstract][Full Text] [Related]
19. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
Bichet DG; Bockenhauer D
Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
[TBL] [Abstract][Full Text] [Related]
20. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
